COMPANY PROFILE

Monarch Bioimplants

NeuroShield is made of naturally occurring Chitosan, which shields nerves from further damage and promotes faster regrowth

Rising Sun, United StatesFounded 2016Biotech & Life Sciences

Valuation $100–250M Last recorded · 2020

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Monarch Bioimplants

Monarch Bioimplants specializes in developing advanced chitosan-based bioimplants designed for peripheral nerve regeneration. The company operates in the biomedical sector, focusing on creating solutions that aid in the recovery of nerve injuries. Monarch Bioimplants serves healthcare providers, particularly those involved in surgical treatments and nerve repair. The business model revolves around the research, development, and commercialization of bioimplants that are fully absorbed by surrounding tissues, minimizing side effects and enhancing patient outcomes. Revenue is generated through the sale of these specialized medical devices to hospitals and clinics. Monarch Bioimplants leverages the natural properties of chitosan, a polysaccharide known for its biocompatibility and bioabsorption, to offer innovative medical solutions. The company aims to improve the quality of life for patients suffering from nerve damage through its cutting-edge technology.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2016
Headquarters: Rising Sun, United States
Open positions: None listed
Dealroom signal: 55.3/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biomedical, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	Aug 2021	$0	—	Checkpoint Surgical	—
EARLY VC✓Equity / VC	Sep 2020	$22M	$88M	Global Emerging Markets	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Monarch Bioimplants website traffic

Latest recorded traffic for Monarch Bioimplants is 150 monthly website visits, down 25% over the last three months.

Latest monthly visits150 3-month web change-25%

Monthly website visitsOct 2020–Jan 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
RTR1 TherapeuticsPharmaceutical therapies targeting neurological, metabolic and infectious conditions	Temecula, United States	Operational	16	$78M	$310M
DTDraig TherapeuticsTargeted neuromodulators for major neuropsychiatric disorders treatment	Cardiff, United Kingdom	Operational
VTVima TherapeuticsOral treatments for dystonia, enhancing mobility and quality of life for over 1 million affected individuals in the US	Cambridge, United States	Operational
SBStemX BioInnovative 3D microtissue models for drug discovery and regenerative medicine research	Leiden, Netherlands	Operational
ASAdalid SciencesAdvanced lipid nanoparticle technology enhancing genomic medicine through innovative drug delivery systems	Prague, Czechia	Operational
STShenzhen Huixin Biomedical TechnologyDeveloping automated exosome purification systems for early cancer diagnosis and treatment applications	Ningbo, China	Operational
MBMeccellis BiotechA company expert in Tissue and Cell Engineering with a diversified offer for multiple surgical specialties	La Rochelle, France	Operational
ALAltachAltach is an NLC venture company	Dublin, Ireland	Operational